Product nameAnti-CXCL7/PBP antibody (Biotin)
See all CXCL7/PBP primary antibodies
DescriptionGoat polyclonal to CXCL7/PBP (Biotin)
Tested applicationsSuitable for: ELISA, WBmore details
Predicted to work with: Human
- WB: Recombinant human CXCL7/PBP protein.
FormLyophilised:Reconstitute in sterile PBS with 0.1% BSA to 0.1 - 1.0 mg/ml.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. Store In the Dark.
Storage bufferConstituents: PBS, 0.1% BSA
Concentration information loading...
Our Abpromise guarantee covers the use of ab271196 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|ELISA||Use a concentration of 0.25 - 1 µg/ml.
Human CXCL7/PBP was detected by sandwich ELISA (using 100μl/well) using a concentration of 0.25-1.0 μg/ml of ab271196. This antibody in conjunction with an appropriate capture antibody, allows the detection of at least 2000-4000 ng/ml of recombinant human CXCL7/PBP protein.
|WB||Use a concentration of 0.1 - 0.2 µg/ml. Predicted molecular weight: 14 kDa.|
FunctionLA-PF4 stimulates DNA synthesis, mitosis, glycolysis, intracellular cAMP accumulation, prostaglandin E2 secretion, and synthesis of hyaluronic acid and sulfated glycosaminoglycan. It also stimulates the formation and secretion of plasminogen activator by human synovial cells. NAP-2 is a ligand for CXCR1 and CXCR2, and NAP-2, NAP-2(73), NAP-2(74), NAP-2(1-66), and most potent NAP-2(1-63) are chemoattractants and activators for neutrophils. TC-1 and TC-2 are antibacterial proteins, in vitro released from activated platelet alpha-granules. CTAP-III(1-81) is more potent than CTAP-III desensitize chemokine-induced neutrophil activation.
Sequence similaritiesBelongs to the intercrine alpha (chemokine CxC) family.
modificationsProteolytic removal of residues 1-9 produces the active peptide connective tissue-activating peptide III (CTAP-III) (low-affinity platelet factor IV (LA-PF4)).
Proteolytic removal of residues 1-13 produces the active peptide beta-thromboglobulin, which is released from platelets along with platelet factor 4 and platelet-derived growth factor.
NAP-2(1-66) is produced by proteolytical processing, probably after secretion by leukocytes other than neutrophils.
NAP-2(73) and NAP-2(74) seem not be produced by proteolytical processing of secreted precursors but are released in an active form from platelets.
- Information by UniProt
- B TG1 antibody
- Beta TG antibody
- Beta thromboglobulin antibody
To detect Human CXCL7/PBP by Western Blot analysis this antibody can be used at a concentration of 0.1 - 0.2 μg/ml.
When used in conjunction with compatible development reagents the detection limit for Recombinant Human CXCL7/PBP is 1.5-3.0 ng/lane, under either reducing or non-reducing conditions.
Lane 1: Marker
Lanes 2-12: 250, 125, 62.5, 31.25, 15.625, 7.8, 3.9, 1.95, 0.975, 0.4875 and 0.24 ng recombinant human CXCL7/PBP, respectively.
Human CXCL7/PBP was detected by sandwich ELISA (using 100 µl/well) using a concentration of 0.25-1.0 µg/ml of ab271196.
This antibody in conjunction with an appropriate capture antibody, allows the detection of at least 2000-4000 pg/mL of recombinant CXCL7/PBP protein.
CXCL7/PBP = NAP-2
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab271196 has not yet been referenced specifically in any publications.